导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.83% | 3320/4773 |
| 近一周 | -2.77% | 3034/5462 |
| 近一月 | -4.65% | 2623/5421 |
| 近一季 | -6.81% | 2209/5209 |
| 近半年 | -4.41% | 2513/4920 |
| 近一年 | -2.09% | 2970/4366 |
| 近两年 | 49.10% | 1494/2954 |
| 近三年 | 25.76% | 1245/2253 |
| 成立以来 | 37.50% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.74% 3929/4961 |
10.30% 2426/5312 |
- - |
- - |
| 2025 | 22.18% 1991/4813 |
-1.70% 2749/3635 |
0.91% 2533/4076 |
24.11% 1494/4524 |
-0.76% 2631/4813 |
| 2024 | 15.85% 871/3463 |
0.66% 946/2808 |
-2.66% 1223/3014 |
18.66% 968/3129 |
-0.35% 1392/3463 |
| 2023 | -14.53% 1607/2656 |
1.59% 1540/2280 |
-5.54% 1492/2385 |
-5.09% 1278/2515 |
-6.17% 1651/2655 |
| 2022 | -20.27% 954/2207 |
-14.31% 933/1919 |
6.73% 621/2016 |
-14.57% 1116/2113 |
2.03% 1060/2208 |
| 2021 | -4.31% 948/1822 |
-5.44% 924/1255 |
5.97% 777/1330 |
-5.81% 863/1466 |
1.39% 949/1822 |
| 2020 | 41.89% 281/1250 |
-6.16% 461/1028 |
13.45% 616/1067 |
17.61% 101/1164 |
13.32% 368/1184 |
| 2019 | 38.93% 295/1092 |
26.13% 425/754 |
-4.24% 423/804 |
3.29% 260/850 |
11.35% 62/918 |
| 2018 | -27.47% 422/834 |
- - |
- - |
- - |
-10.85% 234/691 |
| 2017 | 13.03% 266/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.29% 280/605 |
- - |
- - |
- - |
- - |
| 2015 | 8.23% 171/575 |
- - |
- - |
- - |
- - |
| 2014 | 45.09% 107/237 |
- - |
- - |
- - |
- - |
| 2013 | -13.18% 165/186 |
- - |
- - |
- - |
- - |
| 2012 | 6.33% 69/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 银华中证等权重90指数(LOF) VS. 长安沪深300非周期A(740101) |